Cullinan Therapeutics Inc [CGEM] stock prices are up 1.83% to $11.14 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CGEM shares have gain 7.63% over the last week, with a monthly amount drifted -10.45%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $30 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $40 on May 01, 2024. William Blair initiated its recommendation with an Outperform. Wedbush started tracking with an Outperform rating for this stock on February 15, 2024, and assigned it a price target of $30. In a note dated June 15, 2023, TD Cowen initiated an Outperform rating.
The stock price of Cullinan Therapeutics Inc [CGEM] has been fluctuating between $5.68 and $13.33 over the past year. Currently, Wall Street analysts expect the stock to reach $31 within the next 12 months. Cullinan Therapeutics Inc [NASDAQ: CGEM] shares were valued at $11.14 at the most recent close of the market. An investor can expect a potential return of 178.28% based on the average CGEM price forecast.
Analyzing the CGEM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.42 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.68 points at the first support level, and at 10.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.52, and for the 2nd resistance point, it is at 11.90.
Ratios To Look Out For
It’s worth pointing out that Cullinan Therapeutics Inc [NASDAQ:CGEM]’s Current Ratio is 10.45. Further, the Quick Ratio stands at 10.45, while the Cash Ratio is 3.15.
Transactions by insiders
Recent insider trading involved AHMED NADIM, President and CEO, that happened on Dec 23 ’25 when 9922.0 shares were sold. Chief Scientific Officer, Michaelson Jennifer completed a deal on Dec 19 ’25 to sell 1345.0 shares. Meanwhile, Chief Legal Officer SUMER JACQUELYN L sold 3480.0 shares on Dec 18 ’25.
